BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease modifying agents (DMAs) for the treatment of multiple sclerosis (MS) patients, they are most satisfied with Biogen/Elan's Tysabri. Prescribing of both Tysabri and Novartis's recently launched DMA, Extavia, is anticipated to increase over the next six months with Bayer's Betaferon suffering the most in terms of market share loss...
More...
More...